On May 14, 2026 Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet medical need, reported that it will host a virtual key opinion leader event focused on the evolving clinical and translational data supporting the development of (Z)-endoxifen, the Company’s investigational selective estrogen receptor modulator/degrader, or SERM/D, as a potential next-generation endocrine therapy backbone across multiple estrogen receptor ("ER") -positive breast cancer settings.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The event will feature internationally recognized surgical oncologist and breast cancer expert Dr. Laura Esserman. Dr. Esserman serves as Director of the University of California San Francisco Breast Care Center and is the founder and principal investigator of the I-SPY Trials, an innovative platform designed to accelerate the development of personalized breast cancer therapies.
"Dr. Esserman has been at the forefront of innovation in breast cancer clinical research, adaptive trial design, and precision oncology for decades," said Dr. Steven Quay, M.D., Ph.D., Chairman and Chief Executive Officer of Atossa Therapeutics. "We believe (Z)-endoxifen has the potential to become more than a single-indication therapy; it may serve as an endocrine therapy platform across multiple ER-positive breast cancer settings. Dr. Esserman’s leadership in translational breast cancer research makes her an ideal expert to discuss the emerging clinical and biomarker data supporting this opportunity."
The discussion is expected to address several topics of interest to clinicians, investors, and potential strategic partners, including:
Recent data from the I-SPY2 Endocrine Optimization Pilot study evaluating (Z)-endoxifen as monotherapy in newly diagnosed ER-positive breast cancer patients
Translational biomarker data, including Ki-67 reduction, MRI functional tumor volume changes, and circulating tumor DNA dynamics
Data supporting (Z)-endoxifen activity across clinically relevant ESR1 mutations, including Y537N, Y537S, and D538G
The rationale for (Z)-endoxifen as a potential next-generation endocrine therapy backbone
Combination strategies, including CDK4/6 inhibitor combinations
Development opportunities in premenopausal breast cancer and endocrine therapy optimization
Event Details
Date: Tuesday, May 19, 2026
Time: 1:00 to 2:00 p.m. PT
Moderator: Michael King, Managing Director at Rodman & Renshaw
Registration: View Source
Attendees may submit questions to [email protected] up to 24 hours prior to the event.
A replay of the webcast will be available on the Company’s "Investors" portion of its website for at least 60 days following the live event.
About (Z)-Endoxifen
(Z)-endoxifen is a potent Selective Estrogen Receptor Modulator/Degrader, or SERM/D, with demonstrated activity across multiple mechanisms of action. Atossa is evaluating its potential applications in oncology and rare diseases. The Company’s proprietary oral formulation has shown a favorable safety profile and pharmacology distinct from tamoxifen, including ER-targeted effects and PKC inhibition. Atossa’s (Z)-endoxifen is not approved for any indication.
(Press release, Atossa Therapeutics, MAY 14, 2026, View Source [SID1234665732])